Ross W. Ward

Ross W. Ward

Auto-generated profile, based on publicly available information

Ross W. Ward

Adjuvant Research Group, Trinity Biomedical Sciences Institute School of Biochemistry and Immunology, Trinity College Dublin Dublin 2 Ireland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
ELEdward Lavelle
Edward Lavelle
RWRoss W. Ward
Ross W. Ward

24 January 2025 in Science Advances
Verified
Journal Article
Open access
AZAlessia Zotta
Alessia Zotta
JTJuliana Toller-Kawahisa
Juliana Toller-Kawahisa
EPEva M. Palsson-McDermott
Eva M. Palsson-McDermott
SOShane M. O’cArroll
Shane M. O’cArroll
ÓHÓrlaith C. Henry
Órlaith C. Henry
Luke O'NeillLuke O'Neill
Luke O'Neill
The cytokine interleukin-10 (IL-10) limits the immune response and promotes resolution of acute inflammation. Because of its immunosuppressive effects, IL-10 up-regulation is a common feature of tumor progression and metastasis. Recently, IL-10 regulation has been shown to depend on mitochondria and redox-sensitive signals. We have found that Suppressor of site III Qo Electron Leak 1.2 (S3QEL 1.2), a specific inhibitor of reactive oxygen species (ROS) production from mitochondrial complex III, and myxothiazol, a complex III inhibitor, decrease IL-10 in lipopolysaccharide (LPS)–activated macrophages. IL-10 down-regulation is likely to be mediated by suppression of c-Fos, which is a subunit of activator protein 1 (AP1), a transcription factor required for IL-10 gene expression. S3QEL 1.2 impairs IL-10 production in vivo after LPS challenge and promotes the survival of mice bearing B16F10 melanoma by lowering tumor growth. Our data identify a link between complex III–dependent ROS generation and IL-10 production in macrophages, the targeting of which could have potential in boosting antitumor immunity.

25 July 2025 in Nature Metabolism
Verified
Journal Article
Open access
BKBritta Kunkemoeller
Britta Kunkemoeller
HPHannah Prendeville
Hannah Prendeville
CMClaire McIntyre
Claire McIntyre
ATAyantu Temesgen
Ayantu Temesgen
RLRόisín M. Loftus
Rόisín M. Loftus
LLLydia Lynch
Lydia Lynch
Obesity increases the risk of many cancers and impairs the anti-tumour immune response. However, little is known about whether the source or composition of dietary fat affects tumour growth or anti-tumour immunity in obesity. Here, we show that high-fat diets (HFDs) derived from lard, beef tallow or butter accelerate tumour growth in a syngeneic model of melanoma, but HFDs based on coconut oil, palm oil or olive oil do not, despite equivalent obesity. Using butter-based and palm oil-based HFDs as examples, we find that these dietary fat sources differentially regulate natural killer and CD8 T cell infiltration and function within the tumour microenvironment, governed by distinct effects on the plasma metabolome and intracellular metabolism. We identify diet-related lipid intermediates, namely long-chain acylcarnitine species, as immunosuppressive metabolites enriched in mice fed butter compared to palm oil HFD. Together, these results highlight the significance of diet in maintaining a healthy immune system and suggest that modifying dietary fat may improve cancer outcomes in obesity.

3 August 2021 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
ELEdward Lavelle
Edward Lavelle
RWRoss W. Ward
Ross W. Ward

16 December 2022 in Science Immunology
Verified
Journal Article
Closed access
GSGraeme P. Sullivan
Graeme P. Sullivan
PDPavel Davidovich
Pavel Davidovich
NMNatalia Muñoz-Wolf
Natalia Muñoz-Wolf
RWRoss W. Ward
Ross W. Ward
YSYasmina E. Hernandez Santana
Yasmina E. Hernandez Santana
SMSeamus J. Martin
Seamus J. Martin
Interleukin-1 (IL-1) family cytokines are key barrier cytokines that are typically expressed as inactive, or partially active, precursors that require proteolysis within their amino termini for activation. IL-37 is an enigmatic member of the IL-1 family that has been proposed to be activated by caspase-1 and to exert anti-inflammatory activity through engagement of the IL-18R and SIGIRR. However, here we show that the longest IL-37 isoform, IL-37b, exhibits robust proinflammatory activity upon amino-terminal proteolysis by neutrophil elastase or cathepsin S. In sharp contrast, caspase-1 failed to process or activate IL-37 at concentrations that robustly activated its canonical substrate, IL-1β. IL-37 and IL-36 exhibit high structural homology, and, consistent with this, a K53-truncated form of IL-37, mimicking the cathepsin S–processed form of this cytokine, was found to exert its proinflammatory effects via IL-36 receptor engagement and produced an inflammatory signature practically identical to IL-36. Administration of K53-truncated IL-37b intraperitoneally into wild-type mice also elicited an inflammatory response that was attenuated in IL-36R −/− animals. These data demonstrate that, in common with other IL-1 family members, mature IL-37 can also elicit proinflammatory effects upon processing by specific proteases.

3 December 2023 in European Journal of Immunology
Verified
Journal Article
Open access
JHJorge Huete‐Carrasco
Jorge Huete‐Carrasco
RLRoisin I. Lynch
Roisin I. Lynch
RWRoss W. Ward
Ross W. Ward
ELEdward Lavelle
Edward Lavelle
Vaccination is considered one of the major milestones in modern medicine, facilitating the control and eradication of life‐threatening infectious diseases. Vaccine adjuvants are a key component of many vaccines, serving to steer antigen‐specific immune responses and increase their magnitude. Despite major advances in the field of adjuvant research over recent decades, our understanding of their mechanism of action remains incomplete. This hinders our capacity to further improve these adjuvant technologies, so addressing how adjuvants induce and control the induction of innate and adaptive immunity is a priority. Investigating how adjuvant physicochemical properties, such as size and charge, exert immunomodulatory effects can provide valuable insights and serve as the foundation for the rational design of vaccine adjuvants. Most clinically applied adjuvants are particulate in nature and polymeric particulate adjuvants present advantages due to stability, biocompatibility profiles, and flexibility in terms of formulation. These properties can impact on antigen release kinetics and biodistribution, cellular uptake and targeting, and drainage to the lymphatics, consequently dictating the induction of innate, cellular, and humoral adaptive immunity. A current focus is to apply rational design principles to the development of adjuvants capable of eliciting robust cellular immune responses including CD8+ cytotoxic T‐cell and Th1‐biased CD4+ T‐cell responses, which are required for vaccines against intracellular pathogens and cancer. This review highlights recent advances in our understanding of how particulate adjuvants, especially polymer‐based particulates, modulate immune responses and how this can be used as a guide for improved adjuvant design.